These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12090908)

  • 1. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
    Dzau VJ; Bernstein K; Celermajer D; Cohen J; Dahlöf B; Deanfield J; Diez J; Drexler H; Ferrari R; Van Gilst W; Hansson L; Hornig B; Husain A; Johnston C; Lazar H; Lonn E; Lüscher T; Mancini J; Mimran A; Pepine C; Rabelink T; Remme W; Ruilope L; Ruzicka M; Schunkert H; Swedberg K; Unger T; Vaughan D; Weber M
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):149-60. PubMed ID: 12090908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity.
    Taddei S; Bortolotto L
    Am J Cardiovasc Drugs; 2016 Oct; 16(5):309-21. PubMed ID: 27260014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.
    Stergiou GS; Skeva II
    Curr Top Med Chem; 2004; 4(4):473-81. PubMed ID: 14965313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the renin-angiotensin system: what's new?
    Leckie BJ
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Jan; 3(1):23-32. PubMed ID: 15638741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases.
    Urata H; Nishimura H; Ganten D; Arakawa K
    Blood Press Suppl; 1996; 2():22-8. PubMed ID: 8913536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
    Shah AD; Arora RR
    Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of angiotensin-converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases.
    Magen E; Viskoper RJ
    Isr Med Assoc J; 2000 Dec; 2(12):929-34. PubMed ID: 11344778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE inhibitors: future perspectives.
    Reid JL
    J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S41-3. PubMed ID: 7507539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition.
    Vaughan DE
    Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-34-7. PubMed ID: 9422850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions among ACE, kinins and NO.
    Linz W; Wohlfart P; Schölkens BA; Malinski T; Wiemer G
    Cardiovasc Res; 1999 Aug; 43(3):549-61. PubMed ID: 10690327
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-ischemic potential of drugs related to the renin-angiotensin system.
    Ertl G; Hu K
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S11-20. PubMed ID: 11392474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ACE inhibition on myocardial ischaemia.
    Ferrari R
    Eur Heart J; 1998 Sep; 19 Suppl J():J30-5. PubMed ID: 9796838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rethinking the renin-angiotensin system and its role in cardiovascular regulation.
    Pagliaro P; Penna C
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):77-87. PubMed ID: 15883759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ACE inhibitors--activators of kinin receptors].
    Kugaevskaia EV; Eliseeva IuE
    Biomed Khim; 2011; 57(3):282-99. PubMed ID: 21863742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
    Petrie MC; Padmanabhan N; McDonald JE; Hillier C; Connell JM; McMurray JJ
    J Am Coll Cardiol; 2001 Mar; 37(4):1056-61. PubMed ID: 11263608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition.
    Hanif K; Bid HK; Konwar R
    Hypertens Res; 2010 Jan; 33(1):11-21. PubMed ID: 19911001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular protection: current possibilities and future perspectives.
    Lüscher TF
    Int J Clin Pract Suppl; 2001 Jan; (117):3-6. PubMed ID: 11715356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system.
    Regoli D; Gobeil F
    Can J Physiol Pharmacol; 2017 Oct; 95(10):1117-1124. PubMed ID: 28384411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.